Compare GROW & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | XLO |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 49.8M |
| IPO Year | 1995 | 2021 |
| Metric | GROW | XLO |
|---|---|---|
| Price | $2.69 | $8.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 15.3K | ★ 33.5K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | $23,850,609.00 | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $9.85 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.20 | $0.46 |
| 52 Week High | $3.65 | $9.25 |
| Indicator | GROW | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 53.90 |
| Support Level | $2.35 | $0.62 |
| Resistance Level | $2.73 | $9.03 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 56.03 | 51.88 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.